Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.
Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.
复制标题
Collapsin 反应介导蛋白 4 启动子甲基化水平作为诊断前列腺原发性恶性淋巴瘤的潜在预测因子。
DOI：
10.1186/s12935-017-0484-9
复制
发表时间：
2018
影响因子：
5.8
通讯作者：
Pang J
中科院分区：
文献类型：
--
作者：
Chen Z;Liang Q;Wang J;Huang QX;Chen JN;Weng ZJ;Shao CK;Gao X;Pang J
前列腺原发性恶性淋巴瘤（PMLP）好发于老年人，与乳酸脱氢酶（LDH）、前列腺特异性抗原（PSA）无明显相关性。 PMLP的临床症状和影像学数据仍不具有特异性，预后较差。先前的结果表明，塌陷反应介导蛋白 4 (CRMP4) 启动子甲基化可用作前列腺活检中淋巴结转移的预测因子。然而，CRMP4启动子甲基化与PMLP之间的关系尚未研究。我们研究了 PMLP 的临床病理特征以及 CRMP4 甲基化在 PMLP 中的意义。回顾性分析10例PMLP患者的临床资料和诊断信息。测定10例PMLP患者石蜡包埋组织中CRMP4启动子甲基化水平，然后与局限性前列腺癌（LPCa）及其阴性淋巴结组织[LPCa-LN（−）（10例）]以及转移性前列腺癌（mPCa）及其阳性淋巴结组织[mPCa-LN（+）（10例）]进行比较。对各组CRMP4启动子甲基化进行统计分析。采用受试者工作特征（ROC）曲线分析CRMP4甲基化在PMLP中的诊断价值。 10例PMLP患者、20例前列腺腺癌组织、10例LPCa-LN（-）和10例mPCa-LN（+）组织中CRMP4的平均甲基化值分别为42.3%、30.6%、6.7%和20.3%。 Kruskal-Wallis 检验显示CRMP4 甲基化差异显着（X2 = 38.0，P < 0.001）。 ROC 曲线分析发现，CRMP4 甲基化 > 40.9% 可以诊断 PMLP。在 CRMP4 甲基化 > 40.9% 的条件下，该方法具有 90% 的灵敏度和 95% 的特异性。曲线下面积（AUC）为0.957。 PMLP中CRMP4基因的甲基化显着增加，有望成为PMLP的新预测因子。
Primary malignant lymphoma of the prostate (PMLP) is prone to occur in the elderly, and it has no significant correlation with lactate dehydrogenase (LDH) and prostate specific antigen (PSA). Clinical symptoms and imaging data of PMLP remain unspecific, and its prognosis is poor. A previous result showed that collapsin response mediator protein 4 (CRMP4) promotor methylation can be used as a predictor for lymph node metastases in prostate biopsies. However, the relationship between CRMP4 promotor methylation and PMLP has not been studied. We investigated the clinicopathological features of PMLP and the significance of CRMP4 methylation in PMLP. The clinical data and diagnosis information of 10 patients with PMLP were retrospectively analyzed. The CRMP4 promotor methylation level in paraffin-embedded tissues of the 10 patients with PMLP were determined and then compared to limited prostate cancer (LPCa) and its negative lymph node tissue [LPCa-LN (−) (10 cases)] and also to metastatic prostate adenocarcinoma (mPCa) and its positive lymph node tissue [mPCa-LN (+) (10 cases)]. Methylation of the CRMP4 promotor in each group was analyzed statistically. A receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of CRMP4 methylation in PMLP. The average methylation value of CRMP4 in 10 PMLP patients, 20 cases of prostate adenocarcinoma tissue, 10 cases LPCa-LN (−) and 10 cases mPCa-LN (+) were 42.3, 30.6, 6.7 and 20.3%, respectively. A Kruskal–Wallis test showed that the difference of CRMP4 methylation was significant (X2 = 38.0, P < 0.001). An ROC curve analysis found that CRMP4 methylation > 40.9% could diagnose PMLP. This method had 90% sensitivity and 95% specificity under conditions of CRMP4 methylation > 40.9%. The area under the curve (AUC) was 0.957. Methylation of the CRMP4 gene was significantly increased in PMLP, and it is expected to become a new predictor for PMLP.
登录
查看更多内容
影响因子：
2.9
作者：
Tan F;Thiele CJ;Li Z
通讯作者：
Li Z
影响因子：
5.6
作者：
Chu, PGG;Huang, Q;Weiss, LM
通讯作者：
Weiss, LM
影响因子：
2.9
作者：
Hu S;Wang Y;Yang L;Yi L;Nian Y
通讯作者：
Nian Y
影响因子：
1.3
作者：
Gorgel, Sacit Nuri;Sefik, Ertugrul;Calli, Aylin Orgen
通讯作者：
Calli, Aylin Orgen
DOI：
10.5114/wo.2012.31781
发表时间：
2012
期刊：
Contemporary oncology (Poznan, Poland)
影响因子：
--
作者：
Wang C;Jiang P;Li J
通讯作者：
Li J